Neurogene (NGNE) Asset Writedowns and Impairment (2023 - 2025)

Neurogene's (NGNE) quarterly Asset Writedowns and Impairment came in at $120000.0 in Q4 2025, up 31.87% on a QoQ basis from $91000.0 in Q1 2024.

Analysis

Neurogene (NGNE) Asset Writedowns and Impairment (2023 - 2025) Analysis & Trends

Neurogene (NGNE) has 3 years of Asset Writedowns and Impairment data on file, last reported at $120000.0 in Q4 2025.

Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $120000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $120000.0 (up 31.87% YoY) and the FY2025 annual result came in at $120000.0, up 31.87% from the prior year.
Asset Writedowns and Impairment advanced to $120000.0 in Q4 2025, from $91000.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $120000.0 in Q4 2025 to a low of $91000.0 in Q1 2024.
A 3-year average of $103666.7 and a median of $100000.0 in 2023 frame the typical range for Asset Writedowns and Impairment.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Neurogene	864.53 Mn	864.53 Mn	-

Historic Data

Download Data